# Chaga Conk Mushroom (Inonotus obliquus 'Chaga Conk')

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/chaga-conk-mushroom
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Mushroom/Fungi
**Also Known As:** Inonotus obliquus, Chaga, Chaga mushroom, Birch conk, Black mass, Clinker polypore, Sterile conk trunk rot, Tschaga, Czaga, King of herbs, Diamond of the forest, Kabanoanatake

## Overview

Chaga conk (Inonotus obliquus) is a parasitic fungus growing primarily on birch trees, whose primary bioactive compounds—triterpenoids and betulinic acid derivatives—exert cytotoxic effects against cancer cell lines by inducing apoptosis and disrupting tumor cell proliferation. Preclinical evidence supports anti-tumor and [antioxidant activity](/ingredients/condition/antioxidant), though robust human clinical trials remain limited.

## Health Benefits

• Anti-cancer properties - In vitro studies show triterpenoids with IC50 ≤10 µM against lung adenocarcinoma, breast cancer, colorectal carcinoma (preliminary evidence)
• Tumor growth inhibition - Oral administration (0.2 mg/mouse/day) reduced Sarcoma-180 tumor weight by 33.7% in mice (animal studies only)
• Synergistic chemotherapy support - Digested water extracts showed synergy with cisplatin/trastuzumab in breast cancer cells (in vitro evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects - Reduced edema and cytokines in DSS colitis mouse models (preliminary animal data)
• Cell cycle regulation - Induces G0/G1 arrest in cancer cells, reducing proliferation signals (in vitro studies)

## Mechanism of Action

Chaga's triterpenoids, including inotodiol and betulinic acid, induce apoptosis in cancer cells by activating caspase cascades and downregulating Bcl-2 anti-apoptotic proteins, achieving IC50 values at or below 10 µM against lung adenocarcinoma, breast cancer, and colorectal carcinoma cell lines. Polysaccharide fractions ([beta-glucan](/ingredients/condition/immune-support)s) modulate innate immunity by binding Dectin-1 receptors on macrophages and dendritic cells, stimulating TNF-α and IL-6 [cytokine](/ingredients/condition/inflammation) release. Additionally, melanin-derived compounds and superoxide dismutase (SOD)-like constituents scavenge [reactive oxygen species](/ingredients/condition/antioxidant), contributing to the fungus's antioxidant profile.

## Clinical Summary

The majority of evidence supporting chaga's anti-tumor effects comes from in vitro cell studies and rodent models; no large-scale randomized controlled trials in humans have been completed. In one mouse study, oral administration of chaga extract at 0.2 mg/mouse/day reduced Sarcoma-180 tumor weight by 33.7% compared to controls. In vitro data consistently show IC50 values ≤10 µM for triterpenoid fractions against multiple cancer cell lines, including lung adenocarcinoma and colorectal carcinoma, indicating preliminary cytotoxic potency. Overall, the evidence is considered promising but preliminary, and extrapolation to human therapeutic outcomes requires caution pending clinical trials.

## Nutritional Profile

Chaga conk is nutritionally distinct from culinary mushrooms due to its woody, sclerotium-like structure. Carbohydrates dominate the dry mass (~50-60%), primarily as complex polysaccharides including [beta-glucan](/ingredients/condition/immune-support)s (estimated 2-8% dry weight, predominantly β-1,3/1,6-glucans) and chitin. Protein content is relatively low (~2-5% dry weight), with limited amino acid data available. Fat content is minimal (<1-2% dry weight). Dietary fiber is substantial (~25-35% dry weight) owing to structural polysaccharides and lignin complexes. Key bioactive compounds include: betulinic acid and betulin (derived from birch host bark, ~0.1-1.5% dry weight depending on harvest source), inotodiol and lanosterol-type triterpenoids (~0.2-0.8% dry weight), and melanin-like chromogenic complexes (up to 2-5% dry weight, responsible for the characteristic black exterior). Polyphenol content is notably high (~15-25 mg GAE/g dry weight in water extracts), contributing to strong [antioxidant activity](/ingredients/condition/antioxidant) (DPPH IC50 reported at ~0.14-0.30 mg/mL). Ergosterol (provitamin D2 precursor) is present at ~0.02-0.05% dry weight, lower than soft-bodied mushrooms. Minerals detected include manganese (~4-6 mg/100g dry weight), zinc (~1-2 mg/100g), potassium (~400-600 mg/100g), and iron (~2-4 mg/100g). B-vitamins (B1, B2, B3) are present in trace amounts (<0.5 mg/100g each). Oxalic acid content is notably elevated (~1.5-2.5 g/100g dry weight), posing a bioavailability concern for minerals and a potential risk for oxalate-sensitive individuals. Bioavailability notes: hot water extraction significantly improves polysaccharide and polyphenol bioavailability compared to raw powder; betulinic acid has poor aqueous solubility and low oral bioavailability without lipid co-administration or nanoformulation; beta-glucan bioavailability is enhanced via dual extraction (water + ethanol) methods. Oxalate levels warrant caution in kidney stone-prone individuals consuming concentrated extracts.

## Dosage & Preparation

No clinically studied human dosages are available. In vitro studies used triterpenoids at IC50 ≤10 µM or 0.1-5 mg/mL digested water extract; animal studies used 0.2 mg/mouse/day orally. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Chaga contains high levels of oxalates, and prolonged high-dose consumption has been associated with oxalate nephropathy and kidney damage, as documented in at least one case report of a patient consuming 4–5 teaspoons of chaga powder daily for six months. Because chaga may enhance anticoagulant and antiplatelet effects, concurrent use with warfarin, aspirin, or other blood-thinning medications carries a risk of increased bleeding. Chaga may also exhibit hypoglycemic activity, warranting caution in individuals taking insulin or oral antidiabetic drugs due to potential additive blood sugar lowering. Safety data during pregnancy and lactation are absent, so use is not recommended in these populations.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses are available for Chaga Conk; evidence is limited to preclinical in vitro and in vivo animal studies. Key research includes in vitro assays showing anticancer activity and mouse studies demonstrating tumor suppression, but human clinical validation is lacking.

## Historical & Cultural Context

Chaga has been used for centuries in folk medicine of Russia, China, Korea, and some Western countries as a medicine and health food for general vitality. Historical applications include anti-cancer, [anti-inflammatory](/ingredients/condition/inflammation), [antiviral](/ingredients/condition/immune-support), and antitumor effects, with decoctions or extracts from wild birch conks.

## Synergistic Combinations

Reishi mushroom, Turkey tail, Cordyceps, Vitamin D3, Quercetin

## Frequently Asked Questions

### What is the active compound in chaga mushroom responsible for anti-cancer effects?

The primary anti-cancer compounds in chaga are triterpenoids, particularly inotodiol and betulinic acid derivatives, which have demonstrated IC50 values at or below 10 µM against lung adenocarcinoma, breast cancer, and colorectal carcinoma cells in vitro. These compounds induce programmed cell death (apoptosis) by activating caspase pathways and suppressing Bcl-2 survival proteins in tumor cells.

### How much chaga mushroom should you take per day?

No standardized human clinical dosage has been established for chaga mushroom, as large-scale trials are lacking. Animal research used approximately 0.2 mg of extract per mouse per day to achieve a 33.7% reduction in Sarcoma-180 tumor weight, but this cannot be directly translated to a human dose. Commercially available products typically suggest 500–2000 mg of dried extract daily, though individuals should consult a healthcare provider before use.

### Can chaga mushroom damage your kidneys?

Yes, high-dose or prolonged chaga consumption poses a risk of oxalate nephropathy because chaga contains unusually high concentrations of oxalates. A documented case report described kidney damage in a patient who consumed 4–5 teaspoons of chaga powder daily for six months, resulting in progressive renal insufficiency. People with a history of kidney stones or kidney disease should avoid chaga or use it only under medical supervision.

### Does chaga mushroom interact with blood thinners like warfarin?

Chaga contains compounds that may inhibit platelet aggregation and possess anticoagulant properties, creating an additive bleeding risk when combined with drugs such as warfarin, heparin, aspirin, or clopidogrel. This interaction is based on pharmacological plausibility and case-level evidence rather than formal drug interaction studies. Anyone on anticoagulant or antiplatelet therapy should consult their physician before using chaga supplements.

### Is chaga mushroom the same as reishi or lion's mane?

No, chaga (Inonotus obliquus) is a distinct fungal species from reishi (Ganoderma lucidum) and lion's mane (Hericium erinaceus), differing in morphology, host tree, and primary bioactive compounds. Chaga grows as a black, charcoal-like conk primarily on birch trees and is characterized by its triterpenoid and betulinic acid content, whereas reishi is recognized for ganoderic acids and lion's mane for hericenones that stimulate nerve growth factor (NGF). Each mushroom has a different proposed mechanism of action and distinct research profile.

### What is the difference between chaga conk mushroom and other chaga products like powder or extract?

Chaga conk refers to the raw, woody fungal mass harvested directly from birch trees, while powders and extracts are processed derivatives. Water extraction methods, commonly used for chaga conk, may enhance bioavailability of beta-glucans and polysaccharides but reduce some heat-sensitive triterpenoids. The conk form requires decoction or extended steeping to release active compounds, whereas standardized extracts provide consistent dosing of targeted compounds like inotodiol and lanosterol.

### Is chaga mushroom safe to use alongside chemotherapy treatments like cisplatin?

While in vitro studies suggest chaga water extracts may have synergistic effects with cisplatin, you must consult your oncologist before combining chaga with any chemotherapy, as safety data in humans receiving active cancer treatment is limited. Animal studies do not reliably predict human outcomes, and concurrent use could potentially affect drug metabolism or efficacy. Any supplement use during chemotherapy requires medical supervision and explicit approval from your cancer care team.

### How strong is the clinical evidence supporting chaga mushroom's anti-cancer claims?

Current evidence for chaga's anti-cancer effects is primarily limited to in vitro (test tube) and animal studies, with preliminary data showing triterpenoids inhibiting certain cancer cell lines at concentrations of 10 µM or lower and modest tumor reduction in mice. No peer-reviewed human clinical trials have demonstrated that chaga mushroom prevents or treats cancer in people. While these preclinical results are encouraging for further research, they do not establish chaga as a proven cancer therapy or preventive agent.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*